SCHEMBL13664228

SCHEMBL13664228

CCCCOc1c(Br)c(C(=O)OC)c(-c2c(OCCCC)c(OCCCC)c(OCCCC)c(Br)c2C(=O)OC)c(OCCCC)c1OCCCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 4/20 0.42
THRB P10828 4/20 0.42
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CASP1 P29466 1/20 0.38
CYP1A2 P05177 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ESR1 P03372 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP2D6 P10635 1/20 0.37
PDE4A P27815 1/20 0.37
HIF1A Q16665 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CYP2C19 P33261 1/20 0.36
ALPL P05186 1/20 0.36
MAPT P10636 1/20 0.36
CCNB2 O95067 1/20 0.35
CCNE2 O96020 1/20 0.35
CDK1 P06493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11928634 0.84 GAA (0.37) THRBNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL8551491 0.78 THRA (0.49) THRATHRBNPC1RAB9ACYP1A2
SCHEMBL8548592 0.76 THRA (0.50) THRATHRBRAB9ASMN1; SMN2ESR1
SCHEMBL13662900 0.75 LMNA (0.55) THRATHRBNPC1RAB9ASMN1; SMN2
SCHEMBL13664127 0.75 FFAR4 (0.39) THRATHRBNPC1RAB9AESR1
SCHEMBL8548248 0.75 THRA (0.49) THRATHRBNPC1RAB9ACYP1A2
SCHEMBL13664126 0.74 THRA (0.43) THRATHRBCYP1A2SMN1; SMN2ESR1
SCHEMBL28809090 0.72 RAB9A (0.47) NPC1RAB9ACASP1CYP1A2SMN1; SMN2
SCHEMBL8548540 0.71 THRA (0.44) THRATHRBRAB9ACYP1A2SMN1; SMN2
SCHEMBL12697311 0.70 CYP1A2 (0.51) NPC1RAB9ACASP1CYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270614-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME NAGASE & CO., LTD. (JP) 2009-10-29 US disclosed
EP-1870403-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME NAGASE & COMPANY, LTD. (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270614-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME BCAT1, BCAT2, AADAT THRA 2592/4885THRB 1700/4885NPC1 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.